Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

XBP1s plays a key role in controlling IL-15-mediated NK cell survival, study shows

A new study published in Science Immunology points to a promising therapeutic approach for future cancer treatments based on natural killer cells (NK), which are immune cells that bind to tumor cells and destroy them.

14 Mar 2023

Components of the gut microbiome could be used to better predict efficacy of CAR-T cell therapy

Even though, according to recent preliminary studies, the risk of dying from cancer has declined within the European Union in recent years, cancers remain among the leading causes of death.

13 Mar 2023

Biden administration urged to take more aggressive steps to relieve medical debt

Dozens of advocates for patients and consumers, citing widespread harm caused by medical debt, are pushing the Biden administration to take more aggressive steps to protect Americans from medical bills and debt collectors.

7 Mar 2023

Reprogrammed tumor cells could teach the body's immune system to fight cancer

Some cities fight gangs with ex-members who educate kids and starve gangs of new recruits. Stanford Medicine researchers have done something similar with cancer — altering cancer cells so that they teach the body's immune system to fight the very cancer the cells came from.

2 Mar 2023

University of Vermont Cancer Center to offer a novel, highly effective form of cancer treatment

The University of Vermont Cancer Center will offer a novel, highly effective form of cancer treatment called CAR T-cell therapy beginning in February, when final accreditation and approval to begin treating patients is expected.

24 Feb 2023

Whole genome sequencin provides clearest picture of the genetic changes leading to Hodgkin lymphoma

To create the most effective, personalized treatment plans for patients with Hodgkin lymphoma or other cancers, scientists and clinicians need the clearest picture of the genetic changes leading to the cancer's development.

21 Feb 2023

The prevalence of spike-protein antibodies following at least 3 COVID-19 vaccine doses in immunocompromised individuals

Researchers determined the prevalence of antibodies against the SARS-CoV-2 spike glycoprotein following three or more doses of COVID-19 vaccines among immunocompromised individuals.

17 Feb 2023

Study provides insight into the immune microenvironment around Hodgkin lymphoma tumors

The most comprehensive study to date of the blood cancer, Hodgkin lymphoma, has provided fascinating insights into what tumour cells must do to survive. Researchers from the Wellcome Sanger Institute found that cancer cells use signals to attract certain types of immune cell and instruct them not to attack.

16 Feb 2023

Personalizing CAR-T cell stimulation during manufacturing can enhance its functionality

New adoptive T cell therapies - in which T cells, the immune system's natural hunters patrolling the body for foreign adversaries, are retrieved from cancer-riddled patients, super-charged and amplified outside the body, and then infused back into the same patient - are changing the prospects of cancer patients.

10 Feb 2023

Cancer-causing viruses use a human protein to evade the innate immune response

The viruses Kaposi sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) have been linked to several cancers.

6 Feb 2023

What is the impact of anticancer therapy on patients with hematologic malignancies and COVID-19?

Researchers performed a systematic review and meta-analysis following the PRISMA guidelines.

2 Feb 2023

Chemotherapy in the afternoon proved to be effective for female lymphoma patients

Chemotherapy is a commonly used regimen for cancer treatment, but it is also a double-edged sword. While the drugs are highly effective at killing cancer cells, they are also notorious for killing healthy cells in the body.

27 Jan 2023

Chemotherapy schedule affects treatment outcomes in female DLBCL patients

24 Jan 2023

Mutations may underlie how the most aggressive lymphomas arise and resist therapies

The key to understanding how the most aggressive lymphomas arise and resist current therapies may lie in mutations that disrupt a critical natural selection process among antibody-producing B cells, according to a multi-institutional preclinical study led by Weill Cornell Medicine investigators.

19 Jan 2023

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, "Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001."

18 Jan 2023

The diverse mechanisms by which galectins can regulate adaptive and innate immune responses

Researchers explored ways galectins can impact immunity and discussed the opportunities and challenges in the field.

18 Jan 2023

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two major hallmarks of quality

The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.

18 Jan 2023

Protein discovery could lead to more effective treatments for lymphoma and lung cancer

Scientists from The Australian National University and the Peter MacCallum Cancer Centre have discovered that a protein, called Menin, contributes to abnormal deactivation of specific genes in cancer cells.

13 Jan 2023

Comprehensive atlas of protein kinases could help scientists decipher many cellular signaling pathways

One of the most important classes of human enzymes are protein kinases - signaling molecules that regulate nearly all cellular activities, including growth, cell division, and metabolism.

12 Jan 2023

Simple method increases the efficacy of T cell therapy by cytokine conjugation

The recent years have seen a wave of adoptive cell therapies (ACTs), a type of immunotherapy in which T cells (T cell transfer therapy) and other immune cells are obtained from patients, activated and multiplied outside the body, and infused in larger numbers back into the blood circulation to help fight cancers.

11 Jan 2023

Lymphoma News and Research

Further Reading

XBP1s plays a key role in controlling IL-15-mediated NK cell survival, study shows

Components of the gut microbiome could be used to better predict efficacy of CAR-T cell therapy

Biden administration urged to take more aggressive steps to relieve medical debt

Reprogrammed tumor cells could teach the body's immune system to fight cancer

University of Vermont Cancer Center to offer a novel, highly effective form of cancer treatment

Whole genome sequencin provides clearest picture of the genetic changes leading to Hodgkin lymphoma

The prevalence of spike-protein antibodies following at least 3 COVID-19 vaccine doses in immunocompromised individuals

Study provides insight into the immune microenvironment around Hodgkin lymphoma tumors

Personalizing CAR-T cell stimulation during manufacturing can enhance its functionality

Cancer-causing viruses use a human protein to evade the innate immune response

What is the impact of anticancer therapy on patients with hematologic malignancies and COVID-19?

Chemotherapy in the afternoon proved to be effective for female lymphoma patients

Chemotherapy schedule affects treatment outcomes in female DLBCL patients

Mutations may underlie how the most aggressive lymphomas arise and resist therapies

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

The diverse mechanisms by which galectins can regulate adaptive and innate immune responses

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two major hallmarks of quality

Protein discovery could lead to more effective treatments for lymphoma and lung cancer

Comprehensive atlas of protein kinases could help scientists decipher many cellular signaling pathways

Simple method increases the efficacy of T cell therapy by cytokine conjugation

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News